Session » Antiphospholipid Syndrome Poster

Date: Sunday, November 13, 2022

Time: 9:00AM-10:30AM

Meeting: ACR Convergence 2022

9:00AM-10:30AM: Abstract Number: 0683

ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases: Clinical and Serological Characteristics, Results from the APS ACTION Clinical Database and Repository

9:00AM-10:30AM: Abstract Number: 0682

Analysis of Recurrent Thrombotic Events in a Large Single-center Primary Antiphospholipid Syndrome Cohort: Results from APS-Rio Cohort After over Than 600 Patients-year of Follow-up

9:00AM-10:30AM: Abstract Number: 0686

Anti-β2GP1/HLA-DR Antibody Is Associated with Arterial Thrombosis in Female Patients with Connective Tissue Diseases: A Cross-Sectional Study in Japan

9:00AM-10:30AM: Abstract Number: 0688

Antibodies of the IgA Isotype Target Neutrophil Extracellular Traps in APS

9:00AM-10:30AM: Abstract Number: 0681

Antiphospholipid Antibodies and Incident Cardiovascular Events in a Diverse Population: Results from the Dallas Heart Study

9:00AM-10:30AM: Abstract Number: 0680

Association of Environmental Risk Factors with Antiphospholipid Antibodies and Thrombosis in 1199 International Patients Referred for Suspected Antiphospholipid Syndrome

9:00AM-10:30AM: Abstract Number: 0675

Clinical Characteristics and Factors Associated with Relapse and Mortality in Diffuse Alveolar Hemorrhage Among Patients with Antiphospholipid Syndrome: A Multi-Center Retrospective Cohort

9:00AM-10:30AM: Abstract Number: 0687

DNA- and NET-Binding Beta-2 Glycoprotein I in a Large Cohort of Antiphospholipid Antibody-Positive Patients

9:00AM-10:30AM: Abstract Number: 0694

Evaluation of the Effect of UCB4470 (anti-mouse FcRn) on Amelioration of Thrombosis in a Mouse Model of Antiphospholipid (aPL)-induced Thrombosis

9:00AM-10:30AM: Abstract Number: 0672

Immune Thrombocytopenia Could Be an Independent Phenotype of Primary Antiphospholipid Syndrome

9:00AM-10:30AM: Abstract Number: 0678

Inpatient Epidemiology, Expenditures and Resource Utilization of Antiphospholipid Syndrome: National Inpatient Sample 2019

9:00AM-10:30AM: Abstract Number: 0693

Low Neutrophil Ectonucleotidase Activity Drives Neutrophil-Platelet Aggregation and Platelet Activation in Antiphospholipid Syndrome (APS)

9:00AM-10:30AM: Abstract Number: 0677

Obstructive Sleep Apnea in Primary Antiphospholipid Syndrome Impacts Damage Accrual

9:00AM-10:30AM: Abstract Number: 0673

Occurrence and Severity of Bleeding in Adults with Immunogenic Thrombocytopenic Purpura with or Without Antiphospholipid Autoantibodies

9:00AM-10:30AM: Abstract Number: 0679

Outcomes of Antiphospholipid Antibody Syndrome and Acute Coronary Syndrome: Analysis of National Inpatient Sample

9:00AM-10:30AM: Abstract Number: 0676

Presentation and Outcomes in Patients with Adrenal Hemorrhage Associated with Antiphospholipid Syndrome: A Cohort Study and Systematic Review of Literature

9:00AM-10:30AM: Abstract Number: 0674

Prevalence of Heparin Induced Thrombocytopenia in Hospitalized Patients with Antiphospholipid Syndrome or Systemic Lupus Erythematosus with Antiphospholipid Antibodies

9:00AM-10:30AM: Abstract Number: 0684

Single Antiphospholipid Antibody Positive Thrombotic APS Patients’ Clinical Characteristics: Retrospective Results from the APS ACTION Clinical Database and Repository (Registry)

9:00AM-10:30AM: Abstract Number: 0691

Structural Differences Exist in Beta-2-Glycoprotein I from APS Patients Compared to Healthy Controls

9:00AM-10:30AM: Abstract Number: 0685

The Association of Antiphospholipid Antibodies with Previous SARS-CoV-2 Infection Among Elective Knee Replacement Patients

9:00AM-10:30AM: Abstract Number: 0692

The Interplay Between Lipid Peroxidation and Neutrophil Extracellular Trap (NET) Formation in APS Pathogenesis

9:00AM-10:30AM: Abstract Number: 0690

The Physiological Ketone Body Beta-Hydroxybutyrate Potently Neutralizes APS-Associated NETosis

9:00AM-10:30AM: Abstract Number: 0671

Thrombocytopenia and Autoimmune Hemolytic Anemia in Antiphospholipid Antibody-positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

9:00AM-10:30AM: Abstract Number: 0689

Type I Interferon Stimulated Genes Identify Different Phenotypes of Antiphospholipid Syndrome Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].